GenomiCare Scientific Advisory Board Member Dr. Chen Lieping is elected by National Academy of Sciences as new member

April 28, 2021

On April 27, 2021, the National Academy of Sciences (NAS) announced the latest list of newly elected members, including Dr. Chen Lieping, a member of the GenomiCare Scientific Advisory Board (SAB). Other 6 Chinese scientist were also elected, who are Dr. Cao Hui, Dr. Cai Yifang, Dr.Chang Ta Yuan, Dr. Liu Ruqian, Dr.Kang le, and Dr.Rachel Wong. The National Academy of Sciences is one of the most prestigious academies in the world in recognition of distinguished scientists with original research.

Chen is internationally recognized for his leadership in the field of PD-L1 biology. His work has provided an important foundation for the subsequent development of immunotherapies to enable more effective immune responses against cancer. Chen also initiated and helped organize the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006 and developed PD-L1 staining as a biomarker. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers, which has revolutionized cancer treatment.

In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.

In 1999, Dr. Chen first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by tumors and that its activity can cause T cell dysfunction, thus preventing T cells from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking theinteraction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006 and developed PD-L1 staining as a biomarker. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers, which has revolutionized cancer treatment.

Other important breakthroughs made by Dr. Chen’s laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.

In align with GenomiCare’s vision in providing individualized medical solutions for precision medicine development in China, Dr. Chen has worked closely with GenomiCare as a member of our SAB since establishment. With his support and guidance, GenomiCare has help more than 13,000 Chinese cancer patients to better manage their disease progression and diagnosis, and is dedicated to expanded our services in CLIA/CAP testing and patient-centric services to propel the development of precision medicine in China.

About National Academy of Sciences

The National Academy of Sciences (NAS) was is a United States nonprofit, non-governmental organization established in 1863. NAS is part of the National Academies of Sciences, Engineering, and Medicine, along with the National Academy of Engineering (NAE) and the National Academy of Medicine (NAM). The Proceedings of the National Academy of Sciences (PNAS) was established in 1914 and is one of the most influential international academic journals that publish original research.